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ABSTRACT 
Purpose: In about 10% of patients affected by Fanconi Anemia (FA) the diagnosis is 
delayed until adulthood and the presenting symptom in these “occult” FA is often a 
solid cancer and cancer-treatment related toxicity. Highly predictive clinical 
parameter(s) for diagnosing such an adult onset cases are missing. 
Methods: i) Whole-Exome Sequencing (WES) ii) Sanger sequencing of the FANCA 
gene; iii) DEB-induced chromosome breakage test. 
Results: WES identified a pathogenic homozygous FANCA variant in a patient affected 
by Sertoli Cell Only Syndrome (SCOS) and in his azoospermic brother. Although they 
had no overt anemia, chromosomal breakage test revealed a reverse somatic mosaicism 
in the former and a typical FA picture in the latter. In 27 selected SCOS cases one 
additional patient showing compound heterozygous pathogenic FANCA variants was 
identified with positive chromosomal breakage test. 
Conclusion: We report an extraordinary high frequency of FA in a specific subgroup of  
azoospermic patients (7.1%). The screening for FANCA mutations in such patients has 
the potential to identify undiagnosed FA before the appearance of other severe clinical 
manifestations of the disease. The definition of this high-risk group for “occult” FA, 
based on specific testis phenotype with mild/borderline hematological alterations, is of 
unforeseen clinical relevance. 
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INTRODUCTION 
The severest form of male factor infertility is non-obstructive azoospermia (NOA), 
which occurs in approximately 1% of all men in reproductive age and in the majority of 
patients the etiology remains unknown.1 Since spermatogenesis is regulated by the 
concerted action of >2000 genes, a large proportion of idiopathic NOA might be 
attributable to a not yet identified genetic defect.2 Within the last years, Whole Exome 
Sequencing (WES) has proved to be a powerful tool for the discovery of causative 
variants in familial cases of NOA.3–10 On the other hand, this approach has the potential 
to incidentally reveal undiagnosed diseases. Genes involved in stem cell proliferation 
and DNA repair are important not only for spermatogenesis but also for other 
physiological processes. For instance, the association between FA, caused by mutations 
in genes involved in DNA interstrand cross-link repair, and infertility is well known in 
humans; however, the exact testicular phenotype in FA patients has not been explored. 
FA arises in the large majority of cases with bone marrow failure during childhood 
however, in 10% of cases the diagnosis is delayed until adulthood.11 The late diagnosis 
frequently occurs in those patients who present a slow progressive depletion of bone 
marrow hence the sign of onset may be the appearance of a cancer instead of an overt 
anemia. Diagnosing occult FA has a relevance also concerning cancer treatment due to 
acute toxicity to chemotherapy. We performed WES in an idiopathic NOA (iNOA) 
patient with consanguineous parents, who displayed Sertoli Cell-Only Syndrome 
(SCOS). Our investigation revealed a pathogenic variant in the FANCA gene providing 
an incidental diagnosis of FA during a genetic investigation for NOA in an adult man. 
Based on this finding we revisited all our patients with similar testis histology and 
selected among them those with mild alterations or borderline values of platelets and 
Mean Corpuscular Volume  (MCV) for further screening of FANCA gene mutations. 
This approach has led to the identification of a high-risk group for adult onset FA.  
 
MATERIALS AND METHODS 
Study populations 
4 
 
Study population I: A 43-year-old man (04-170) with iNOA and with consanguineous 
parents (first-cousin marriage) was selected for WES. All known causes of azoospermia 
were excluded. Testis histology revealed SCOS type I (no germ cells were present in the 
tubules). See Table 1. 
Study population II: 27 iNOA patients with testis histology of SCOS type I and SCOS 
type II (SCOS with germ cells in a minority of tubules), with platelets <200.000/L and 
MCV>85fL were selected for FANCA mutation screening (Table S1).  
Whole Exome Sequencing (WES) in patient 04-170 
Library preparation, Bioinformatic analysis and variants filtering are described in 
Supplementary Material. 
Multiplex Ligation-Dependent Probe Amplification (MLPA) 
Large deletions were analyzed using a Multiplex Ligation-Dependent Probe 
Amplification (MLPA) kit developed by MRC-Holland BV as we described before.12  
FANCA Sanger sequencing analysis 
Two-steps Sanger Sequencing (described by Castella et al. 2011)12 in 27 selected iNOA 
patients: first, the three most commonly mutated exons (exons 13, 36, 38) in the Spanish 
population; second, the remaining FANCA exons.  
Diepoxibutane (DEB)-induced chromosomal breakage test: mutation carrier NOA 
patients and and their brother’s peripheral blood lymphocytes, as described elsewhere13 
(see also Supplementary Material). 
Gene Expression Evaluation 
Quantitative RT-PCR (qRT-PCR) analysis was performed to evaluate FANCA 
expression in adult testes biopsies, collected in our clinic and characterized with 
molecular markers for the definition of distinct germ cell types (details in 
Supplementary Material and Table S2). 
 
RESULTS 
Exome analysis of a NOA patient affected by SCOS 
Patient 04-170 carried a total of 20477 exonic variants. Following standard filtering 
(described in supplementary material) and the exclusion of synonymous variants with a 
MAF≥0.05, we filtered for all homo/hemizygous variants that presented an in-house 
Index of Pathogenicity (IP) ≥0.7. Of the eight resulting variants, only one mapped to a 
gene with proved implication in spermatogenesis (FANCA) and presented the highest 
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pathogenic score (IP=0.9,) (Figure 1, Figure S1 and Table S3). The c.2639G>A variant  
maps to exon 28 of the FANCA gene (NM_000135.2) and its pathogenicity was proven 
by functional studies12,14 . It was already shown to cause FA in a Spanish  patient,12 as 
well as  reported in the FA Mutation Database at Rockefeller University both in 
homozygosis and heterozygosis in eight FA patients (Table S4). DEB-induced 
chromosomal breakage test, one of the gold-standard tests used in the routine practice 
for the diagnosis of FA, gave a positive result in a fraction of cells, indicating FA 
somatic mosaicism (Figure 1B). The presence of 2-3% of wild-type alleles in the NGS 
data (data not shown) suggests a possible mechanism of genetic revertion by back 
mutation.  The confirmation of this hypothesis would request  additional experiments 
using digital PCR, cloning and single clone sequencing or amplicon analysis by deep 
NGS15. 
Following the discovery of the variant, the patient, during genetic counseling, informed 
the doctor that also his brother suffered by azoospermia. The screening of FANCA in his 
brother revealed the same genotype. The man could not undergo physical examination 
in our clinic due to geographic distances, but according to the family doctor he has no 
evident skeletal abnormalities or other FA-related symptoms. DEB-induced 
chromosomal breakage test showed that the majority of cells resulted positive, revealing 
a typical complete FA picture (Figure 1B). It is interesting to note that although this 
man presented a mild decrease of platelets in 2011 and, as for 2013 he also displayed a 
mild decrease of red blood cells and leucocytes, this condition was not further explored 
by the family doctor. The hemogram from 2016, requested after our diagnosis, shows a 
pronounced decrease of all three cell types (Table 1).  
FANCA mutation screening in selected iNOA patients with SCOS   
From our large cohort of 1300 infertile men, 136 were classified as iNOA with testis 
histology of SCOS type I or type II. For 120/136 patients hematological parameters 
were available and we selected those (n=27) with platelets <200.000/L and Mean 
Corpuscular Volume >85fL (Figure S2, Table S1). Genomic DNA from peripheral 
blood of this specific group of 27 iNOA patients was screened for mutation firstly in 
exons 13, 36, 38 i.e. those exons which contain the most commonly observed mutations 
in Spanish FA patients and for large FANCA deletions through MLPA. We identified a 
heterozygous variant in exon 38 in patient 14-339 [NM_000135.2:c.3788_3790delTCT, 
p.Phe1263del)]. This analysis was followed by Sanger sequencing of the entire FANCA 
gene which revealed a second heterozygous variant in exon 39 
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[NM_000135.2:c.3913C>T ,p.Leu1305Phe] in patient 14-339.  Both mutations were 
previously reported in many FA patients and are clearly pathogenic (Figure S2, Table 
S4). Similar to patient 04-170, DEB-induced chromosomal breakage test gave a positive 
result in a fraction of cells confirming mosaic FA (Figure S3). The brother of this 
patient showed normozoospermia and his hormone levels, testis volume and blood 
count were within the normal range (Table 1). Sanger Sequencing revealed only one of 
the two variants in heterozygosis [NM_000135.2:c.3913C>T, p.Leu1305Phe]. 
FANCA expression in the testis: qRT-PCR analysis was performed in a collection of 
testis biopsy samples (not belonging to the patients’ testis biopsies due to the lack of 
material recollection) previously characterized by a molecular genetic approach (see 
Supplementary Material). FANCA was undetectable in SCOS, but showed the highest 
expression in biopsies with a prevalent spermatogonial arrest (SGA) and obstructive 
azoospermia (i.e. presence of all spermatogenesis stages). This expression pattern is 
compatible with a prevalent expression in spermatogonial and early spermatocytic stage 
(Figure S4). . 
 
DISCUSSION 
The large majority of FA patients are diagnosed in childhood due to the presence of 
significant birth defects. About 10% of patients the diagnosis is delayed until 
adulthood,11 especially when they appear normal or have subtle findings that may be 
overlooked. The late diagnosis frequently occurs in those patients who present a slow 
progressive depletion of bone marrow hence the sign of onset may be the appearance of 
a cancer instead of an overt anemia. According to the FA Guidelines,16 “male 
infertility” is one of those adult-onset signs/symptoms which should raise suspicion of 
FA, hence should prompt clinicians to perform peripheral blood testing. However, while 
FA is a rare disease (prevalence of 1/160.000), infertility is a common pathological 
condition, present in 7% of the general male population. Moreover, it is an extremely 
heterogeneous condition ranging from the complete absence of spermatozoa in the 
ejaculate (azoospermia) to decreased sperm number or motility/morphology.1 Even the 
NOA phenotype can be further sub-classified according to the testis histology e.g. 
complete absence of germ cells (SCOS), spermatogenic arrest (at different stages) or 
hypospermatogenesis. Therefore, referring to “infertility” as a possible FA sign is 
extremely broad and requires a more precise definition in the clinical practice.  
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Our first patient, diagnosed through WES, presented borderline values of blood counts 
and besides infertility showed another potential FA sign, mild dysmorphic facies. His 
brother with the same reproductive problem carried the same genotype and as expected, 
the chromosomal breakage test confirmed FA in both brothers. A picture of mosaic FA 
in patient 04-170 and a complete FA in his brother who did not show dysmorphic 
features but displayed a progressive impairment of hematopoiesis reaching to 
pathologically low values at the control in 2016 (performed after our diagnosis). 
The third patient presented low stature and some cafe au lait spots in his hands and 
back; however, FA was not suspected until he came to our clinic and was diagnosed 
with azoospermia. Similar to patient 04-170, DEB test showed a picture of mosaic FA 
also in this man. The Patient 14-339’s brother carried only one of the variants in 
heterozygosis and his testicular function was normal. A common feature of all three 
affected men were their testis phenotype i.e. SCOS. 
In this study, we report an unexpectedly high frequency of FA (2/28=7.1% or 3/29 = 
10.3% if we consider also the brother) in a specific subgroup of iNOA subjects with 
testicular phenotype of SCOS type I or type II and with slightly altered/borderline 
hematological parameters. Our study indicates that andrological evaluation, especially 
in SCOS patients, should not only include hormone measurement but also blood count, 
since it may lead to the diagnosis of unsuspected FA in adulthood. It further supports 
that FA is not an exclusive childhood illness, and diagnosis and treatment are no longer 
exclusively performed by pediatricians. We propose that the evaluation of 
hematological parameters, in particular platelet count and MCV in NOA patients should 
be included in the routine andrological workup. Vice versa, we provide a more precise 
andrological criteria to all clinicians, about the type of “infertility” subgroup in which 
the likelihood of FA is relatively high. The combined assessment of testis histology and 
hematological parameters allows the diagnosis of “occult” FA before the appearance of 
severe pathologies related to this disease (e.g. hematological malignancies and specific 
solid cancers). It has been reported that in more than 20% of patients with FA who 
developed solid tumors, the diagnosis of FA was made only after the appearance of their 
cancer and its treatment.17 (some genotoxic anticancer agents are contraindicated in FA 
patients because of their DNA repair deficiency).The diagnosis of FANCA variants in 
these three men has also relevance in case they develop this type of cancers in the future 
and thanks to our investigation, they are now receiving specific medical attention 
including strict follow-up by oncohematologists. The link between severe 
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spermatogenic impairment and chronic diseases has been advocated by epidemiological 
observations, showing that infertile men (oligo/azoospermic) have a higher risk of 
morbidity (including cancer) and a lower life expectancy.18–20 A biological basis for 
such observations may be: i) the previously observed high CNV burden2 (indicating 
chromosomal instability) in infertile men; ii) that some genes involved in 
spermatogenesis may also have a role in carcinogenesis (especially those involved in 
stem cell renewal/differentiation and mismatch repair mechanisms21). Besides its 
clinical importance, our study stimulates further investigations on the discovery of 
common genetic factors involved both in SCOS and bone marrow failure.  
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Table 1. Clinical characteristics of the patients carrying FANCA variants and of their 
brothers 
SCOS type I: Sertoli Cell Only Syndrome without germ cells in all tubules; SCOS type II:  Sertoli Cell Only Syndrome with germ 
cells in a minority of tubules. n.a. not available  
 04-170 04-170 
brother 
14-339 14-339 
brother 
Andrological/ Endocrine and metabolic parameters 
Semen phenotype/ 
Testis histology 
Azoospermia/ 
SCOS type I 
Azoospermia/ 
not 
performed 
Azoospermia/ 
SCOS type II 
Normozoo-
spermia 
Age at first semen 
analysis/Testis biopsy 
32 n.a 34 33 
Testis volume, left;right 
(ml) 
5; 12 n.a. 12; 10 25; 25 
 
Relevant clinical findings 
Bilateral 
cryptorchdism;  
mild dismorphic 
facies 
n.a 
Low stature, 
cafe au lait 
spots 
No 
FSH (IU/L) 
25.6 
23.3 
21.3 4.54 
LH (IU/L) 
5.9 10.2 7.53 4.9 
T  (nmol/L) 
15.3 8.2 20.2 18.8 
Height  (cm) 
175 
178 158 179 
BMI (kg/m2) 26.12 
26.51 20.83 20.29 
Glycaemia (mmol/L) 
5.7 
4.61 5.3 5.0 
Cholesterol 
(mmol/L) 
3.47 
5.19 4.2 4.61 
Hematological parameters 
Erythrocyte(1012/L) 
Reference Values: 4.30-6.00 
4.94 4.27 3.43 4.86 
Hemoglobin (g/L) 
Reference Values: 140-180 
161 136 132 145 
Hematocrit (L/L) 
Reference Values: 0.40-0.52 
0.48 0.40 0.38 0.43 
Leucocytes (109/L) 
Reference Values: 4.00-10.50 
4.02 3.02 3.70 5.39 
Platelets (109/L) 
Reference Values: 150-400 
194 116 137 174 
MCV (fL) 
Reference Values: 80-100 
98.10 92.97 112.30 89.30 
MCH (pg) 
Reference Value 27-34 
32.60 31.85 38.60 29.80 
Neutrophils 
Reference Values: 50-70 
49.30% 48.00% 49.60% 43.50% 
Lymphocytes 
Reference Values: 16-45 
36.10% 41.10% 32.90% 38.60% 
Monocytes 
Reference Values: 3-12 
9.60% 9.30% 15.90% 8.20% 
Eosinophils 
Reference Values: 0.40-6.60 
1.10% 1.30% 1.10% 9.10% 
Basophils 
Reference Values < 1.00 
0.40% 0.30% 0.50% 0.60% 
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FIGURE LEGEND 
Figure 1. Investigation on the patient 04-170 and his brother, both carriers of the 
FANCA variant. A) The inverted pyramid scheme indicates how WES data were 
filtered and prioritized for patient 04-170 starting from a total of 20477 variants. Eight 
homozygous, rare and potentially pathogenic variants were identified in eight different 
genes (in bold gene expressed in testis). B) Graphic representation of the chromosomal 
breakage test for patient 04-170 and his brother. The arrows illustrate the patient’s  and 
his brother’s  position in relation to the distribution of historical data collected in our 
laboratory according to the percentage of DEB-induced aberrant cells and the number of 
breakages in each DEB-induced aberrant cell. In the No FA group only individuals with 
at least one aberrant cell were included. C) The pedigree structure shows the segregation 
of the c.2639C>T (p.Arg880Gln) variant. Colored symbols are explained in the legend 
in the lower part of the figure. The lower-left arrow indicates the proband 04-170 who 
was subjected to WES analysis whereas his brother’ DNA was sequenced by Sanger 
sequencing .. Our patient and his brother both carried the c.2639G>A (p.Arg880Gln) 
variant in homozygosis and were azoospermic. The parents’ DNA samples were not 
available for testing, but being the variant rare it can be assumed that the parents were 
both heterozygous carriers 
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Supplementary Materials and Methods 
 
Whole-exome Sequencing 
The analysis (starting from the standard DNA quality check) has been provided as 
SERVICE by BGI (BGI TECH SOLUTIONS (Hong Kong). The description below 
derives from the limited information provided by the company. 
After the standard DNA quality control steps, whole‐ exome sequencing capture was 
performed using the BGI Human 59M Exon kit based on Combinatorial Probe‐ Anchor 
Ligation (cPAL™) technology1 and the captured material was sequenced on Complete 
Genomics platform as service. According to the information provided by the service 
provider, the qualified genomic DNA was randomly fragmented to an average size of 
200-400 bp and then, AdA 5'- and 3'-adaptors were ligated to the 5'- and 3'-ends of the 
fragments, respectively. The AdA adaptor-ligated fragments were amplified by PCR, 
and the PCR products were used for the follow-up exon captured (BGI exome V4, 
59Mb). 
During the exon capture, the exon fragments hybridized with the capture RNA 100nt kit 
probes stably and were therefore captured effectively. The captured exon fragments 
were purified by DynabeadsM-280 Streptavidin Bead purification and were further 
amplified by another round PCR. Then, the PCR products were circularized and the 
resulting double strand (ds) circles were digested with Ecop15. Among these digested 
fragments, small fragments were collected after bead purification. Similar to the AdA 
adaptor ligation, AdB were ligated to both end of the purified fragments 
(aforementioned). These fragments were denatured into two single strands (ss) and the 
target strands were selected for the circularization. The ss circles as templates were 
amplified to be DNA nanoballs (DNBs). DNBs were loaded on the slides and 
sequenced on the Complete Genomics' platform with a 100x mean coverage depth. 
 
Bioinformatic analysis 
Sequence reads were mapped to the reference genome (GRCh37) and variants were 
called in the aligned genome according to the methods described by Carnevali et al 
20122 using version 2.4 of the Complete Genomics software. Briefly, exome reads were 
analyzed using a proprietary technology based on Teramap for alignment on GRCh37 
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(hg19) reference sequence. Variants with low-quality reads were excluded to guarantee 
≥ 80% of bases with quality score of ≥Q20. According to the alignment results, regions 
of the genome deemed likely to differ from the reference genome were identified. Then, 
individual reads that were likely to lie in those regions were collected and a local de 
novo assembly was performed. Next, based on the initial mapping and assembly results, 
a probability statistical model (Bayesian Modeling) was applied to call variants by 
computing a probability ratio for any two hypotheses from the optimization step; variant 
calls are then made based on the most likely hypothesis according to this Bayesian 
probability model. Variants extracted from those hypotheses with a likelihood 
exceeding the significance threshold were reported.  
 
Variants filtering 
Firstly, standard filtering was applied to all samples. Briefly, we selected missense 
variants, stop gains/losses, frameshift insertions/deletions, and filtered out common 
polymorphisms (≥5% in the general population) after consulting the dbSNP 138 and the 
1000G (http://www.1000genomes.org). After applying the abovementioned filter, we 
filtered for hemizygous and homozygous variants for which the global minor allele 
frequency (MAF) was ≤0.05 or not reported. Overall, obtained data was further filtered 
according to their potentially damaging effect depending on the type of variant. For 
SNVs, the prediction of pathogenicity was based on SIFT, Polyphen2, Mutation Taster, 
Mutation Assessor, RadialSVM, LRT and LR prediction tools. An index of 
pathogenicity was created as a score calculated on the basis of the seven prediction tools 
employed, each providing a value ranging from -1 (null probability of being a 
deleterious variant) to 1 (full probability of being a deleterious variant), as illustrated in 
Table S3. Not all prediction tools were always available; therefore a ratio was calculated 
between the summary score of pathogenicity and the number of prediction tools 
available for a determined variant (see table S3) We filtered in variants with  IP>0.7 
which corresponds to an arbitrary threshold, which means that the majority (not 
necessary all) of the interrogated tools gave a “pathogenic” score.  We considered of 
further interest only filtered homozygous variants that were present in genes with 
potential implication in the early phases of spermatogenesis (Figure S1A). Concerning 
indels and nonsense variants prediction tools are not always available, a different 
approach was employed for the selection of candidate variants: all patient-specific 
homo/hemizygous variants with MAF≤0.01 were filtered in. For all variants, SNVs and 
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indels, a thorough investigation of the literature (including papers which are dealing 
with genes involved in azoospermia in consanguineous families) and on-line databases 
was performed to select variants in genes that had a potential role in the early phases of 
spermatogenesis. Genes for which no data on fertility were available as well as genes 
with no putative implication in the early stages of spermatogenesis were excluded 
(Figure S1B). Then the Integrative Genomics Viewer (IGV) was employed to exclude 
eventual false positive calls and variants prioritized as described above were validated 
by Sanger sequencing (Figure S1A).  
Molecular characterization of testis biopsy samples 
RNA was isolated from snap frozen adult testis biopsies collected from azoospermic 
patients with different testis histology (obstructive azoospermia with normal 
spermatogenesis, SCOS, spermatogenic arrest at various stages). The molecular 
characterization consisted in the expression analysis of four genes known to be 
expressed in different stages of spermatogenesis: DAZ (spermatogonia/early 
spermatocytes), CDY1 (Spermatids), BRDT (pachytene spermatocytes/round and 
elongating spermatids) and PRM2 (spermatids/mature spermatozoa). The housekeeping 
reference gene was GAPDH. Based on the obtained expression profiles we selected 
three SCOS sample, one with spermatogenic arrest predominantly at spermatogonial 
stage (SGA), one sample with spermatocytic arrest (SCA) and two samples with 
obstructive azoospermia (OA) i.e. conserved spermatogenesis including mature 
spermatozoa. The extraction was performed through a combination of two 
commercially available kits, the TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) 
and the AllPrep DNA/RNA kit (Sigma-Aldrich, St. Louis, MO, USA), according to the 
manufacturer’s instructions. cDNA synthesis was carried out using the High-Capacity 
cDNA Reverse Transcription Kit (Lifetechnologies, Foster City, CA, USA). qRT-PCR 
was performed using the TaqMan® Universal PCR Master Mix (Lifetechnologies, 
Foster City, CA, USA) with the following standard thermal cycler conditions: 40 cycles 
at 95 °C for 30 seconds and 60 °C for 1 min. Commercially available assays were 
employed to evaluate gene expression of four genes used for characterization(BRDT, 
CDY1, DAZ, PRM2) , the target gene (FANCA) and GAPDH, as reference gene for 
relative quantization of the target gene (Table S2).qRT-PCR runs were performed on a 
StepOne™ System (Applied biosystems, Carlsbad, CA, USA). Experiments were run in 
triplicates. Results concerning FANCA gene expression in the different testis biopsies 
are reported in Figure S4. 
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Detailed description of Diepoxibutane (DEB)-induced chromosomal breakage test 
Three blood cultures were prepared for each patient, including 0.5 ml of blood in 
heparin and 4.5 ml of culture consisting of 15% fetal bovine serum, 1% antibiotics, 1% 
L-glutamine and 1% phytohaemagglutinin in RPMI (all reagents from Gibco, Carlsbad, 
CA, USA). Twenty four hours after culture set-up, two cultures were treated with DEB 
at a final concentration of 0.1 ug/ml (Sigma, Cat. No 202533, St. Louis, MO, USA), and 
the remaining culture was left untreated for spontaneous chromosome fragility 
evaluation. Forty-six hours after DEB treatment, colcemid was added at a final 
concentration of 0.1 ug/ml. Cultures were harvested 2 h later when metaphase spreads 
were obtained according to standard cytogenetic methods and finally, stained with 
Giemsa. For chromosome fragility evaluation, 25-50 metaphases with 46 centromeres 
were analyzed for each culture. The microscopic analysis was performed with a 
LeitzAristoplan microscope and, later with a Zeiss Imager M1 microscope coupled to a 
computerassisted metaphase finder (Metasystems, Altlussheim, Germany). The main 
criteria for the determination of chromosome fragility were as follows: gaps were not 
counted as chromosome breaks and figures were converted to the minimum number of 
breaks necessary to form each figure. DEB stock was routinely replaced every 6 
months. Before using a new lot, a control fragility assay was performed using an FA 
lymphoblastoid cell line to ensure that there was no significant variation between lots.
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Figure S1. Flowchart inherent to 
the exome analysis of patient 04-
170. 
The scheme briefly resumes how 
variants were filtered and then 
prioritized in patient 04-170, 
reaching to the identification and 
validation of the FANCA variant. 
A) Criteria used for filtering (after 
standard quality control) and 
prioritization; B) List of the 
filtered variants and their 
prioritization according to their 
expression in testis and their index 
of pathogenicity (IP). The only 
gene with testis expression is 
reported in bold (FANCA). 
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Figure S2. Flowchart reporting the study design leading to the identification of FANCA mutation carriers. A) The patient analyzed by Whole exome 
Sequencing and the mutation identified is reported. B) The scheme briefly resumes the criteria according to which infertile patients were selected and their 
DNA sequenced based on their testis histology, hematological parameters and genetic finding 
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Figure S3. Investigation on the patient 14-339 and his brother. Graphic representation of the 
chromosomal breakage test for 14-339. The graph illustrates the patient’s position (*) in relation 
to the distribution of historical data collected in our laboratory. The pedigree structure shows the 
segregation of the p.Phe1263del and p.Leu1305Phe. Colored symbols are explained in the 
legend in the lower part of the figure. Patient 14-339 and his brother were sequenced for 
FANCA mutations. The lower-left arrow indicates the proband 14-339. The brother who was 
normozoospermic only carried the p.Leu1305Phe variant in heterozygosis. The parents’ DNA 
samples were not available for testing, but being the variant rare it can be assumed that the 
parents were both heterozygous carriers
10 
 
 
 
 
 
Figure S4. Expression evaluation of the FANCA gene 
Quantitative RT-PCR (qRT-PCR) analysis was performed to 
evaluate FANCA expression in biopsy samples of different types of 
adult testis histologies: i) three SCOS (Sertoli Cell-Only 
Syndrome); ii) one SGA: maturation arrest at the spermatogonial 
level; iii) one SCA: maturation arrest at the spermatocytic level. 
Two samples with obstructive azoospermia (OA) were used as 
internal controls. Samples were first characterized by testing for 
four spermatogenic markers expressed at different stages of 
spermatogenesis: PRM2 (spermatids/mature spermatozoa); CDY1 
(spermatids); BRDT (pachytene spermatocytes/round and 
elongating spermatids) and DAZ (spermatogonia/early 
spermatocytes)
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Table S1. Clinical characteristics of the 27 selected iNOA patients for FANCA gene mutational screening 
Patient code 
Semen 
Phenotype 
Testicular 
phenotype 
Platelets 
(109/L) 
MCV (fL) Erythrocytes (1012/L) Leucocytes (109/L) Neutrophils (%) 
14-339* Azoospermia SCOS type II 137 112.3 3.43 3.7 49.5 
10-331 Azoospermia SCOS type II 103 93.1 4.75 6 46.4 
11-332 Azoospermia SCOS type I 116 90.6 4.43 3.8 56.9 
10-281 Azoospermia SCOS type I 135 99.2 4.82 6.95 55.7 
11-585 Azoospermia SCOS type I 142 92.2 5.41 5.24 54.4 
12-603 Azoospermia SCOS type I 156 89.5 4.59 7.46 57.8 
12-612 Azoospermia SCOS type I 159 92.9 3.09 6.06 60.4 
09-195 Azoospermia SCOS type II 165 85.1 5.23 8.82 75.8 
10-203 Azoospermia SCOS type II 166 89.2 5.76 7.15 54.3 
08-457 Azoospermia SCOS type I 175 85.1 5.24 5.71 45.7 
16-394 Azoospermia SCOS type II 175 89.1 5.13 4.51 48.8 
05-205 Azoospermia SCOS type I 176 89.5 4.76 7.48 86.7 
06-111 Azoospermia SCOS type II 177 85.7 4.61 4.56 50.2 
07-411 Azoospermia SCOS type I 177 88.5 5.02 7.9 59.7 
04-164 Azoospermia SCOS type II 178 86.8 5.59 7.64 58.0 
11-381 Azoospermia SCOS type I 182 86.3 4.84 5.8 56.0 
15-546 Azoospermia SCOS type I 182 93.9 4.91 7.7 55.4 
07-478 Azoospermia SCOS type I 182 93.1 5.21 6.86 54.2 
10-324 Azoospermia SCOS type I 183 93.8 4.49 4.97 40.2 
15-547 Azoospermia SCOS type I 187 93 4.59 7.56 50.5 
15-368 Azoospermia SCOS type I 188 88.9 4.77 5.07 51.4 
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Patient code 
Semen 
Phenotype 
Testicular 
phenotype 
Platelets 
(109/L) 
MCV (fL) 
Erythrocytes 
(1012/L) 
Leucocytes 
(109/L) 
Neutrophils 
(%) 
06-183 Azoospermia SCOS type II 188 88.3 5.3 11.88 64.9 
09-263 Azoospermia SCOS type II 191 88.1 5.61 9.4 60.2 
11-417 Azoospermia SCOS type I 193 86.2 5.15 6.55 58.3 
14-277 Azoospermia SCOS type I 196 88.7 5.13 6.85 52.9 
14-313 Azoospermia SCOS type I 197 92.9 4.79 6.55 60.8 
10-393 Azoospermia SCOS type I 200 85.1 5.74 8.82 54.2 
*Patient 14-339 carrying 2 heterozygous pathogenic mutations in FANCA gene. Reference value for erythrocytes: 4.3-6.0x1012/L; MCV: 80-
100fL; Leucocytes 4.0-10.5x109/L; Neutrophils: 50-70%; Platelets: 150-400109/L 
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Table S2. Commercially available TaqMan gene expression assays in testis 
biopsies. 
Gene Function Assay ID 
FANCA Target gene Hs01116668_m1 
DAZ Spermatogonia/early spermatocytes 
biomarker 
Hs00414014_m1 
CDY1 Spermatids biomarker Hs00371514_m1 
PRM2 Spermatids/mature spermatozoa 
biomarker 
Hs04187294_g1 
BRDT Pachytene spermatocytes/round and 
elongating spermatids 
Hs00976114_m1 
GAPDH Reference housekeeping gene Hs0275891_g1 
  
14 
 
Table S3. Algorithms employed to calculate the index of pathogenicity for variant 
prioritization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Index of pathogenicity (IP) was calculated according to the following formula:  
 
 
 
 
 
Where k= number of available prediction tools. 
Algorithm Prediction Meaning Numeric value (u) 
SIFT T tolerated -1 
 D damaging 1 
 NA not assigned 0 
Polyphen B Benign -1 
 P probably damaging 0.5 
 D damaging 1 
 NA not assigned 0 
Mutation Assessor N neutral -1 
 L low -0.5 
 M medium 0.5 
 H high 1 
 NA not assigned 0 
RadialSVM T tolerated -1 
 D damaging 1 
 NA not assigned 0 
MutationTaster P polymorphism -1 
 D damaging 1 
 NA not assigned 0 
LRT N tolerated -1 
 D damaging 1 
 NA not assigned 0 
LR T tolerated -1 
 D damaging 1 
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Table S4. Variants detected in FANCA gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Fanconi anemia Mutation Database at Rockefeller University (LOVD) https://databases.lovd.nl; +Mankad et al. 20063; £Castella et al. 20114 
 
 
 
 
 
 
Patient 
code 
Mutation Status 
Functional study 
available 
Previously reported 
04-170 & brother 
NM_000135.2: c.2639C>T 
(p.Arg880Gln) 
Homozygosis Yes+ 
Reported in 8 FA 
patients*. Described in 
monozygotic twins 
without hematological 
signs+ 
14-339 
NM_000135.2: 
c.3788_3790delTCT  
(p.Phe1263del) 
Heterozygosis Yes£ 
Reported in 287 FA 
patients*.  
NM_000135.2:c.3913C>T 
(p.Leu1305Phe) 
Heterozygosis Yes£ 
Reported in 5 FA 
patients*. 
14-339’s brother 
(Not affected) 
NM_000135.2:c.3913C>T 
(p.Leu1305Phe) 
Heterozygosis Yes£ 
Reported in 5 FA 
patients*. 
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